Leading the Next CRISPR Revolution
EmendoBio is a pioneering, next generation CRISPR-based therapeutics company.
Our unique approach to developing novel treatments for challenging diseases allows us to make any gene targetable, transforming the current landscape of genetic medicine. Founded and managed by a core group of experts from the Weizmann Institute of Science, EmendoBio’s scientific team combines expertise in protein engineering, molecular biology, and gene editing systems. Our gene editing technology platforms enable us to perform precision gene editing while maintaining high efficiencies, allowing us to address disorders and diseases that were previously considered incurable.
